Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Deals Medical Device

Mirxes XtalPi AI Platform Targets Asian GI Cancers

Fineline Cube Dec 8, 2025

Mirxes Holding Company Limited (HKG: 2629) announced it has entered into a memorandum of understanding...

Company Deals Drug

Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal

Fineline Cube Dec 8, 2025

Sirnaomics Ltd. (HKG: 2257) announced a global non‑exclusive licensing agreement with ChemPartner Co., Ltd. (SHE:...

Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025

The National Healthcare Security Administration (NHSA) released the 2025 National Medical Insurance Drug List and...

Company Deals

OTR Therapeutics Series-A Raises $100M for Neurology Pipeline

Fineline Cube Dec 8, 2025

OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing,...

Company Deals

Sanofi Completes Vicebio $1.6B Acquisition, Adds RSV Vaccine Platform

Fineline Cube Dec 5, 2025

Sanofi (NASDAQ: SNY) announced the completion of its $1.6 billion acquisition of Vicebio, first announced in...

Company Drug

Juventas CAR-T LBCL Launch Marks Second Indication

Fineline Cube Dec 5, 2025

Juventas Cell Therapy Ltd announced the commercial launch of inaticabtagene autoleucel for relapsed or refractory...

Company Drug

BMS Breyanzi MZL FDA Approval First CAR-T

Fineline Cube Dec 5, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the FDA has approved Breyanzi (lisocabtagene maraleucel; liso-cel)...

Company Deals

Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient

Fineline Cube Dec 5, 2025

Formosa Pharmaceuticals, Inc. (TPE: 6838) announced an exclusive licensing agreement with Rxilient Medical Pte. Ltd.,...

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Fineline Cube Dec 4, 2025

Novo Nordisk (NYSE: NVO) reported at the Clinical Trials on Alzheimer’s Disease conference that semaglutide...

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Fineline Cube Dec 4, 2025

Acotec Scientific Holdings Limited (HKG: 6669) announced it has received registration approval from China’s National...

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Fineline Cube Dec 4, 2025

Youjia Biomedical Technology and Hangzhou Tongee Medical Technology Co., Ltd officially signed a strategic cooperation...

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod

Fineline Cube Dec 4, 2025

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its FXS0887 tablet has...

Company Drug

TransThera Tinengotinib Cholangiocarcinoma Priority Review China

Fineline Cube Dec 4, 2025

TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the...

Company Deals R&D

Bio-Sincerity UCAS R&D Center Pharma Synthesis

Fineline Cube Dec 4, 2025

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) announced the signing of a cooperation agreement with...

Company Drug

Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss

Fineline Cube Dec 4, 2025

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...

Company Drug

Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma

Fineline Cube Dec 4, 2025

Beijing Gene Mink Biotechnology announced that its self-developed QM103 Cell Injection, a BCMA‑targeted CAR‑NK cell...

Company Drug

CSPC SYH2056 FDA Approval Targets Depression with 5-HT2A Agonist

Fineline Cube Dec 4, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056 tablets, a Category 1 chemical drug, has...

Company Drug

Antengene XPOVIO sNDA Hong-Kong Approval Expands MM DLBCL Indications

Fineline Cube Dec 4, 2025

Antengene Corporation Limited (HKG: 6996) announced that Hong Kong’s Department of Health approved two supplementary...

Company Drug

Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership

Fineline Cube Dec 4, 2025

Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324,...

Policy / Regulatory

NHSA Guangzhou Drug-List Conference Releases 2025 Medical Insurance Formulary

Fineline Cube Dec 4, 2025

The National Healthcare Security Administration (NHSA) announced it will host the 2025 Innovative Drugs High-Quality...

Posts pagination

1 … 95 96 97 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.